Result of retail offer and Director shareholding

7th September 2023 - 1:50 pm

ImmuPharma Plc is pleased to announce that further to the Company’s announcement at 7:02 a.m. on 31 August 2023, the Company has conditionally raised gross proceeds of £130,683 through the issue of 6,534,150 New Ordinary Shares at a price of 2 pence to existing retail investors of the Company, via the Winterflood Retail Access Platform (“WRAP”), in addition to the £1.35 million raised in the Subscription and Direct Subscription.

An application has been made to the London Stock Exchange for the 6,534,150 new Ordinary Shares to be admitted to trading on AIM. Admission is expected to take place, and dealings on AIM in the Retail Offer Shares are expected to commence, at 8.00 a.m. on or around 12 September 2023.

Director Dealing

Lisa Baderoon, Director, subscribed for 1,000,000 Retail Offer Shares in the Retail Offer. Following Admission, Lisa Baderoon’s shareholding will be 1,583,963 Ordinary Shares comprising 0.38% of the issued share capital.

Total Voting Rights

 Following Admission, the Company will have 416,437,265 Ordinary Shares in issue. Since the Company currently holds no shares in treasury, the total number of voting rights in the Company will therefore be 416,437,265. These figures may therefore be used by Shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change in their interest in, the share capital of the Company under the FCA’s Disclosure Guidance and Transparency Rules.

Capitalised terms used but not defined in this announcement have the same meanings as set out in the announcement of the Company at 7:02 a.m. on 31 August 2023.

To download this announcement click here

Share this article